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Abstract 
Objective. Informed choice is a fundamental concept within prenatal care. The present study 
assessed the extent to which the introduction of non-invasive prenatal diagnosis (NIPD) of Down's 
syndrome may undermine the process of making informed choices to undergo prenatal testing or 
screening for Down's syndrome by altering the quality and quantity of pre-test counselling. 
Methods. 231 obstetricians and midwives were randomly allocated one of three vignettes, each 
describing a different type of test: (a) invasive prenatal diagnosis (IPD), (b) non-invasive prenatal 
diagnosis (NIPD) or (c) Down's syndrome screening (DSS). Participants were then asked to complete 
a questionnaire assessing (1) the information considered important to communicate to women, (2) 
whether test offer and uptake should take place on different days, and (3) whether signed consent 
forms should be obtained prior to testing. 
Results. Across the three test types, five out of the seven presented topics were considered equally 
important to communicate, including the information that testing is the woman's choice. Compared 
with participants receiving the IPD vignette, those receiving the NIPD and DSS vignettes were less 
likely to report that counselling and testing should occur on different days (IPD 94.7% versus 74.1% 
and 73.9% for NIPD and DSS respectively, p = .001) and that written consent was a necessity (IPD 
96.1% versus 68.3% and 75.4% for NIPD and DSS respectively, p < .001). 
Conclusion. This study provides the first empirical evidence to demonstrate that practitioners may 
view the consent process for NIPD differently to IPD. There is potential for the introduction of NIPD 
to undermine women making informed choices in the context of prenatal diagnostic testing for 
conditions like DS. 
Practice implications. Given the importance of informed choice in reproductive decision-making, 
implementation of any programme based on NIPD should be designed to facilitate this. 
 
Keywords: Informed choice; Prenatal; Down's syndrome; Non-invasive testing 
2 |  P a g e
 
Introduction 
Recent reports have described the non-invasive diagnosis of Down's syndrome (DS—a genetic 
disorder characterised by an extra copy of chromosome 21) by analysis of foetal nucleic acids in the 
maternal plasma [1] and [2]. Whilst research is still in its infancy, and it is as yet unclear whether this 
test will replace DS screening as well as diagnostic testing, these advances have the potential to 
transform antenatal practice by superseding current diagnostic tests with non-invasive alternatives 
that do not entail a risk of miscarriage and which might be conducted at an earlier stage in 
pregnancy [1] and [2]. Despite the obvious benefits of such developments, there are concerns that 
non-invasive tests may compromise informed decision-making [3]. 
The importance of facilitating informed choice in the context of prenatal testing services is 
universally endorsed by policy makers. This is evident in the published guidelines that govern service 
delivery [4], [5], [6] and [7] as well as in the ethics literature [8]. Such guidelines stress the 
importance of communicating three sets of information: (1) a description of the condition for which 
testing is being offered, (2) an outline of test characteristics, and (3) the implications of possible test 
results. Written consent may serve as one means of ensuring that an understanding of the testing 
procedure has been achieved [9]. 
A major concern of women currently undergoing prenatal diagnostic testing is the risk of miscarriage 
associated with the invasive procedure [10]. As NIPD removes the need to discuss procedure related 
risks, the decision-maker may fail to adequately consider the remaining implications of test 
outcomes. These include discussion of the option of pregnancy termination if test results indicate an 
affected foetus. The widespread introduction of non-invasive procedures may also lead to a 
‘routinisation’ of prenatal testing. Previous studies in the context of prenatal screening have shown 
that rates of informed choice are higher if screening is perceived as optional as opposed to routine 
[11] and [12]. Given that service providers’ attitudes towards the conduct of prenatal screening have 
the potential to affect their practice [13], the likelihood of any prenatal test becoming ‘routinised’ 
may, in part, depend on health professionals’ attitudes towards its delivery. If perceptions of the 
counselling needed for NIPD are more akin to those for screening, the introduction of these tests 
may have the potential to erode informed choice. 
Whilst concerns about the impending introduction of non-invasive prenatal diagnosis upon informed 
decision-making have been expressed [3], we are unaware of any empirical data to confirm or refute 
such concerns. In anticipation of its implementation in clinical practice we present here the first 
study providing evidence concerning the potential for non-invasive prenatal tests to erode informed 
choice. The aim of the current study is to describe and compare the attitudes of health care 
professionals already involved in the delivery of prenatal services towards those characteristics of 
counselling that are likely to facilitate informed decision-making in the contexts of (a) invasive 
prenatal diagnosis (IPD—amniocentesis or chorionic villus sampling), (b) non-invasive prenatal 
diagnosis (NIPD) and (c) Down's syndrome screening (DSS—a blood test which gives a risk ratio for 
the disorder). 
Methods 
A vignette study, with a between-subjects design, was used to assess the impact of three types of 
prenatal tests on the delivery of prenatal counselling: (a) invasive prenatal diagnostic tests (IPD), (b) 
non-invasive prenatal diagnosis (NIPD) and (c) Down's syndrome screening (DSS). 
Participants 
Participants were health care professionals currently involved in the provision of prenatal testing 
attending at three conferences. Only participants practicing in the UK were included in the final 
sample. Four hundred and seven health professionals were approached to take part in the study, of 
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whom 248 (158 recruited at a conference, 90 recruited from three UK maternity units) agreed to 
participate. 17 (6.9%) individuals attending the conferences did not practice in the UK and hence 
were subsequently excluded from the analyses, leaving a total of 231 study participants (141 from 
the conference, 90 from maternity units). The demographic composition of this sample is provided 
in Table 1. 
 
    Table 1.    Participants’ demographic characteristics and responses to the outcome measures. 
     Total IPD NIPD DSS p-Value 
    Number of 
subjects (n) 
231 76 82 73  
    Mean age (years, 
SD) 
39.7 (10.1) 38.6 (9.7) 37.8 (9.8) 37.3 (9.3) .724 
      
    Gender (%) .262 
     Male 20.3 22.4 14.6 24.7  
     Female 79.7 77.6 85.4 75.3  
      
    Profession (%) .226 
     Obstetrician 59.3 57.9 57.3 63.0  
     Midwife 29.9 36.8 28.2 24.2  
     Other 10.8 5.3 14.6 12.3  
      
    Topics important to communicate (% of respondents who identified topic) 
     Description of 
Down's syndrome 
85.7 84.2 90.2 82.2 .324 
     Her personal 
risk 
92.2 94.7 92.7 89.0 .423 
     The procedure 
itself 
64.1 86.8 40.2 67.1 <.001 
     Likelihood of 
miscarriage 
63.2 90.8 39.0 61.6 <.001 
     Likelihood of 
test not giving 
result 
70.6 71.1 76.8 63 .168 
Testing/screening 
is a choice 
96.5 94.7 98.8 95.9 .357 
     Options 
available if test 
positive 
90.9 86.8 93.9 91.8 .290 
    Timing presentation and uptake test (%) .001 
     Same day 19 5.3 25.9 26.1  
     Different days 81 94.7 74.1 73.9  
      
    Perceived need for written consent (%) <.001 
     Definitely yes 47.2 63.2 36.6 42.5  
     Probably yes 32.5 32.9 31.7 32.9  
     Probably not 17.3 3.9 28.2 19.2  
     Definitely not 3.0 0 3.7 5.5  
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Materials 
Three vignettes were developed and pre-piloted in small sub-sample of 31 health professionals and 
ethicists to gauge the appropriateness and clarity of the information contained therein. Any 
information considered problematic by the majority of these respondents was altered according to 
the recommendations given. Each vignette required participants to imagine working in an antenatal 
clinic at a point in time when all pregnant women are routinely offered prenatal testing for DS. 
Vignettes varied in terms of test type (IPD, NIPD, DSS) and accordingly, their respective 
specifications, i.e. the predictive power of the test (99%, 80%) and the presence or absence of a 
procedure related risk of miscarriage (Box 1) [5]. 
Box 1. Vignettes 
Invasive prenatal diagnosis (IPD) 
Imagine yourself in 5 years’ time. You are working in an antenatal clinic at a time when all pregnant women 
are routinely offered a diagnostic test for Down's syndrome, for example amniocentesis or CVS. Sarah Jones is 
10 weeks pregnant and visits the clinic to be seen by you. You are discussing this test with Sarah. 
You know that invasive tests, which will detect more than 99% of pregnancies affected by Down's syndrome, 
carry a small procedure related risk of miscarriage. 
As this is Sarah's first pregnancy she is not likely to be familiar with the diagnostic test. 
Non-invasive prenatal diagnosis (NIPD) 
Imagine yourself in 5 years’ time. You are working in an antenatal clinic at a time when all pregnant women 
are routinely offered a diagnostic test for Down's syndrome. Sarah Jones is 10 weeks pregnant and visits the 
clinic to be seen by you. You are discussing this test with Sarah. 
Imagine that at this point in time Down's syndrome can be diagnosed non-invasively using a sample of 
maternal blood. This blood test will detect more than 99% of pregnancies affected by Down's syndrome and 
does not carry a procedure related risk of miscarriage like amniocentesis. 
As this is Sarah's first pregnancy she is not likely to be familiar with the diagnostic test. 
Down's syndrome screening (DSS) 
Imagine yourself working in an antenatal clinic at a time when all pregnant women are routinely offered 
prenatal screening for Down's syndrome. The screening test is a blood test, which will detect 80% of 
pregnancies affected with Down's syndrome and has a false positive rate of 3%. Sarah Jones is 10 weeks 
pregnant and visits the clinic to be seen by you. You are discussing this test with Sarah. 
There is no direct procedure related risk involved with the blood test, but if the test is positive, amniocentesis 
or CVS is required for a definitive diagnosis. 
As this is Sarah's first pregnancy she is not likely to be familiar with either the screening or diagnostic test. 
Following the presentation of these vignettes, participants were given two tasks: 
    Task 1: Participants were asked to imagine counselling a pregnant woman at her first visit to the 
antenatal clinic. 
    Task 2: Participants were asked to advise a clinic manager on service organisation for the test 
presented in the vignette. 
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Measures 
Attitudes towards aspects of pre-test counselling likely to facilitate informed choice were assessed 
using a questionnaire. These were (1) the information considered important to communicate during 
counselling, (2) the timing of the test and (3) the perceived need to sign a consent form. 
1)     Type of information considered important to communicate: 
    This was assessed in response to Task 1 (advising a pregnant woman) by asking participants to 
select the topics, from a list of seven possibilities (see Table 1) that they believed should be 
incorporated into a counselling session. 
2)    Timing of the test: 
    Attitudes towards the timing of the test were assessed in response to Task 2 (advising a clinic 
manager). Participants were informed that the test can either be performed on the same day as it is 
offered or on a return visit, thereby providing women with some time for reflection. Participants 
were asked to imagine advising a manager either way. 
3)     Perceived need to sign a consent form: 
    This was assessed in response to Task 2 with the question: ‘Do you think it is important for women 
undergoing this test to sign a consent form?’ Responses were measured on a 4-point scale ranging 
from 1, definitely yes to 4, definitely not. This response format was used to allow those with varying 
degrees of uncertainty to indicate either a general sense of favourableness or unfavourableness. In 
order to generate a binary outcome for multivariate analyses, this variable was dichotomised into 
‘Yes’ and ‘No’ by collapsing ‘definitely’ and ‘probably’. See Table 1 for non-dichotomised data. 
Demographic details (age, gender, and profession) were recorded by participants in the 
questionnaire. 
Procedure 
The study was approved by a research ethics committee in the UK (King's College London Research 
Ethics Committee 05/06-141). Recruitment of participants was opportunistic and took place at three 
professional educational meetings convened in the UK that were predominantly attended by 
obstetricians and midwives (n = 141). The recruitment procedure at the conferences involved 
inserting questionnaires in conference packs. At the beginning of each meeting conference 
organisers brought attention to their presence and asked that individuals either posted responses in 
the pre-paid envelopes provided or left them at a designated place in the auditorium. An additional 
sample of 150 obstetricians and midwives from three UK maternity units were also invited to take 
part in the study. These individuals were sent one of the three vignettes and the associated 
questionnaire via internal post. Non-responders were sent one reminder. An online random number 
generator was used to randomise the order in which vignettes were presented. Participants were 
provided with a pre-paid envelope to return their completed questionnaires. 
Analysis 
Distributions of responses for categorical variables and differences in means for continuous variables 
were examined descriptively across groups. A series of univariate analyses was conducted across 
test types to compare three characteristics of prenatal counselling: topics considered important to 
communicate, timing of the test, and the perceived need for written consent. These were conducted 
using χ2 for categorical variables and ANOVAs for continuous variables. Significant differences were 
examined further with post hoc analyses. Logistic regression analyses were conducted to identify 
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independent predictors of beliefs about the timing of the test and the perceived need to sign a 
consent form. 
 
Results 
The response rate was 61% (248/407 participants, of whom 17 were ineligible because they were 
not practicing in the UK). The majority of respondents were obstetricians (59.3%), female (79.7%) 
with a mean age of 39.7. Age, gender, profession and data source (i.e. the conference or maternity 
unit) were distributed evenly across intervention groups. An overview of the distribution of 
demographic background variables and responses to the three components of counselling across 
intervention groups is displayed in Table 1. 
Topics important to communicate 
Five of the seven topics presented were considered equally important to communicate across 
experimental conditions. These were ‘a description of Down's syndrome’, ‘communication of her 
personal risk’, ‘likelihood of the test not giving a result’, ‘the fact that testing/screening is a choice’ 
and ‘options available if the test confirms Down's syndrome’. Respondents who received the IPD 
vignette considered two of the seven topics, ‘the procedure itself’ and ‘the likelihood of miscarriage’, 
more important to communicate compared with respondents who received the NIPD or the DSS 
vignettes (χ2 = 37, df = 2, p < .001, χ2 = 45, df = 2, p < .001). 
Timing of the test 
Test type affected beliefs about the timing of the test; 94% of respondents who received the IPD 
vignette indicated that the presentation and uptake of prenatal tests should occur on different days 
(χ2 = 14, df = 2, p = .001) ( Table 1), compared with 74% of respondents who received either the 
NIPD or the DSS vignettes. Post hoc analyses confirmed that timing preferences differed significantly 
between NIPD and IPD (χ2 = 12, df = 1, p < .001) but not between NIPD and DSS. 
Perceived need to sign a consent form 
Perceived need to sign a consent form varied by test type (χ2 = 23, df = 6, p = .001): 96% of 
respondents who received the IPD vignette believed that testing should definitely or probably be 
preceded by written consent, compared with 68% and 75% of respondents who received the NIPD or 
DSS vignettes respectively. Post hoc analyses confirmed that the distribution of responses in the 
NIPD condition differed significantly from the IPD condition (χ2 = 22, df = 3, p < .001) but not from 
the DSS condition. 
Two multiple logistic regression analyses were conducted to identify independent predictors of (a) 
preference (Table 2) for test offer and uptake to occur on different days and (b) the perceived need 
(Table 3) for written consent. Test type was identified as the only independent predictor of both 
preference for separated test offer and uptake and the need for written consent. Age, gender and 
profession each had no effect. 
    Table 2.  Predictors of preference for test presentation and uptake to occur on different days. 
  Predictors OR 95% CI p-Value 
    Age 1.01 .97–1.06 .52 
    
    Gender    
     Male 1.0   
     Female 1.20 .49–2.90 .70 
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    Profession    
     Obstetrician 1.0   
     Midwife 1.56 .59–4.11 .37 
     Other 1.06 .37–3.07 .91 
    
    Test type    
     IPD 1.0   
     NIPD .16 .05–.51 .002 
     DSS .17 .05–.52 .002 
    −2ll = 200, model χ2 = 19, HL χ2 = 3.13, p = .93. 
 
    Table 3. Predictors of perceived need for written consent. 
    Predictors OR 95% CI p-Value 
    Age 1.04 1.00–1.08 .08 
    
    Gender    
     Male 1.0   
     Female .70 .28–1.72 .43 
    
    Profession    
     Obstetrician 1.0   
     Midwife .823 .33–2.06 .68 
     Other 1.26 .43–3.72  
    
    Test type    
     IPD 1.0   
     NIPD 12.03 3.40–42.65 <.001 
     DSS 7.57 2.07–27.69 .002 
    −2ll = 197, model χ2 = 28, HL χ2 = 7.84, p = .45. 
 
Discussion 
This study provides the first empirical evidence to suggest that practitioners will view the consent 
process for prenatal diagnostic testing differently depending upon whether it is an invasive or non-
invasive test. This has the potential to undermine women making informed choices about non-
invasive testing based on the assumption that separating in time test offer and test procedure 
facilitates informed choices, as might the process of seeking written consent. Given the rapid 
development of NIPD [14], considering the implications of these findings for clinical practice 
becomes urgent. 
 
Conclusion 
Our ability to draw firm conclusions from the data presented here is limited by the extent to which 
the measures used can be considered valid indices of informed choice. Despite the fact that 
separating test offer and uptake provides time for reflection, there is no empirical evidence to 
support or indeed refute the implicit assumption that this period of reflection actually facilitates 
informed choice. Whilst conducting counselling and testing on the same day has been associated 
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with higher uptake rates, immediate choices to undergo screening are not necessarily less well 
informed [15]. One observational study found rates of informed choice to be higher in the context of 
same day counselling and testing [16], although when this was experimentally manipulated no 
difference was found [17]. Moreover, the removal of the procedure related risk in NIPD may 
conceivably facilitate rather than impede value-consistent choices by reducing the ambivalence 
associated with invasive testing, a situation in which parents are asked to pit the risk to the baby 
against gaining knowledge about potential foetal abnormalities [18]. 
Presently, there is an absence of evidence to substantiate the assumption that obtaining written 
consent in the context of clinical practice aids patient understanding and helps facilitate informed 
choice, nonetheless it is recommended practice [6]. Studies exploring written consent in the context 
of clinical research have generated mixed results with some showing no differences in 
comprehension between oral and written consent and others suggesting that written consent, in 
combination with an oral explanation, leads to better retention [19]. Whilst our results suggest that 
the information provided to individuals is likely to remain unaffected by whether testing is invasive 
or not, knowledge is only one component of an informed choice. The extent to which people act 
consistently with their values is also important in relation to testing decisions, and may be more 
affected by service organisation than aspects of pre-test counselling [20] and [21]. 
The strength of the current study is that it is, to our knowledge, the first to anticipate the 
implications for the quality of women's decision-making of the impending introduction of NIPD into 
clinical practice. The use of an experimental design strengthens the conclusion that health care 
professionals are likely to approach counselling and service provision of non-invasive diagnostic tests 
in a clinically significantly different way to invasive procedures. The extent to which this will erode 
women making informed choices and how best this can be prevented must await further study after 
implementation and will require comparing the actual content of counselling provided to women 
undergoing invasive, non-invasive and screening procedures. 
 
Practice implications 
If NIPD is allowed to develop along the lines suggested by this empirical study, there is a danger that 
current universal guidelines favouring informed choice might be undermined. For this reason, it is 
imperative that standards for the practice of NIPD need to be developed in order that present 
guidelines continue to be adhered to. If NIPD does transform Down's syndrome testing in such a way 
that current screening and diagnostic tests form part of the same procedure, this technology may 
also have wider economic and societal implications, affecting both health care resources and 
attitudes towards disability. Future research in this area would benefit from the use of validated 
measures of informed choice in the context of prenatal diagnosis, further investigation into the 
value of current informed consent procedures in facilitating informed choice, and assessment of 
women and health professionals’ views of pre-test counselling once NIPD has been implemented. 
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